SCHEMBL4255129

SCHEMBL4255129

CC(C(=O)O)(C(=O)O)c1csc(N)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.45
HSD17B10 Q99714 2/20 0.44
GABRA5 P31644 1/20 0.44
GABRB2 P47870 1/20 0.44
ALDH1A1 P00352 7/20 0.41
KDM4E B2RXH2 2/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
NOS1 P29475 1/20 0.41
HPGD P15428 1/20 0.40
HTT P42858 1/20 0.40
NPC1 O15118 4/20 0.39
MEN1 O00255 3/20 0.39
RAB9A P51151 3/20 0.39
KMT2A Q03164 3/20 0.39
MAPT P10636 3/20 0.39
KDM6B O15054 1/20 0.37
KDM4A O75164 1/20 0.37
KDM4B O94953 1/20 0.37
KDM5C P41229 1/20 0.37
KDM5B Q9UGL1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27370392 0.79 GABRA5 (0.46) TSHRHSD17B10GABRA5GABRB2ALDH1A1
SCHEMBL20640303 0.78 GABRA5 (0.44) TSHRHSD17B10GABRA5GABRB2ALDH1A1
SCHEMBL9355256 0.77 TSHR (0.45) TSHRHSD17B10GABRA5GABRB2ALDH1A1
SCHEMBL13609550 0.77 TSHR (0.61) TSHRHSD17B10GABRA5GABRB2ALDH1A1
SCHEMBL3605034 0.76 SMN1; SMN2 (0.46) TSHRHSD17B10GABRA5GABRB2ALDH1A1
SCHEMBL27675797 0.76 TSHR (0.41) TSHRHSD17B10GABRA5GABRB2ALDH1A1
SCHEMBL77483 0.76 SMN1; SMN2 (0.50) TSHRHSD17B10ALDH1A1SMN1; SMN2NOS1
SCHEMBL21044247 0.74 TSHR (0.48) TSHRHSD17B10GABRA5GABRB2ALDH1A1
SCHEMBL4763217 0.74 MEN1 (0.40) TSHRHSD17B10GABRA5GABRB2ALDH1A1
SCHEMBL28763146 0.73 TSHR (0.41) TSHRHSD17B10GABRA5GABRB2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090281142-A1 THIAZOLE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-11-12 US disclosed
EP-1921074-A1 THIAZOLE DERIVATIVE Astellas Pharma Inc. (JP) 2008-05-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281142-A1 THIAZOLE DERIVATIVE GK, GCKR, AK2 TSHR 1234/4885HSD17B10 827/4885GABRA5 1780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.